| pubmed-article:14654558 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C0012984 | lld:lifeskim |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C1416655 | lld:lifeskim |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C0334664 | lld:lifeskim |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C0031715 | lld:lifeskim |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C1690540 | lld:lifeskim |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:14654558 | lifeskim:mentions | umls-concept:C1142954 | lld:lifeskim |
| pubmed-article:14654558 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:14654558 | pubmed:dateCreated | 2003-12-5 | lld:pubmed |
| pubmed-article:14654558 | pubmed:abstractText | The purpose of this study was to evaluate the effect of the receptor tyrosine kinase inhibitor SU11654 on the activity of its molecular target KIT in canine mast cell tumors (MCT) and correlate target inhibition with mutational status of the c-kit juxtamembrane domain and SU11654 plasma concentration. | lld:pubmed |
| pubmed-article:14654558 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14654558 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14654558 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14654558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14654558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14654558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14654558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14654558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14654558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14654558 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14654558 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:14654558 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:14654558 | pubmed:author | pubmed-author:CherringtonJu... | lld:pubmed |
| pubmed-article:14654558 | pubmed:author | pubmed-author:YuXiaomingX | lld:pubmed |
| pubmed-article:14654558 | pubmed:author | pubmed-author:LondonCheryl... | lld:pubmed |
| pubmed-article:14654558 | pubmed:author | pubmed-author:LeeLeslie BLB | lld:pubmed |
| pubmed-article:14654558 | pubmed:author | pubmed-author:SukbuntherngJ... | lld:pubmed |
| pubmed-article:14654558 | pubmed:author | pubmed-author:PryerNancy... | lld:pubmed |
| pubmed-article:14654558 | pubmed:author | pubmed-author:ZadovaskayaRe... | lld:pubmed |
| pubmed-article:14654558 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14654558 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:14654558 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:14654558 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14654558 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14654558 | pubmed:pagination | 5729-34 | lld:pubmed |
| pubmed-article:14654558 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:meshHeading | pubmed-meshheading:14654558... | lld:pubmed |
| pubmed-article:14654558 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14654558 | pubmed:articleTitle | Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. | lld:pubmed |
| pubmed-article:14654558 | pubmed:affiliation | SUGEN, Inc., South San Francisco, California 94080, USA. npryer@ravenbio.com | lld:pubmed |
| pubmed-article:14654558 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14654558 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14654558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14654558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14654558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14654558 | lld:pubmed |
